These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 31474357)

  • 1. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
    Li TJ; Wang WQ; Yu XJ; Liu L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
    Zhang S; Bai X; Shan F
    Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preface: More than two decades of modern tumor immunology.
    Galluzzi L; Rudqvist NP
    Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
    [No Abstract]   [Full Text] [Related]  

  • 12. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.
    Aslan K; Turco V; Blobner J; Sonner JK; Liuzzi AR; Núñez NG; De Feo D; Kickingereder P; Fischer M; Green E; Sadik A; Friedrich M; Sanghvi K; Kilian M; Cichon F; Wolf L; Jähne K; von Landenberg A; Bunse L; Sahm F; Schrimpf D; Meyer J; Alexander A; Brugnara G; Röth R; Pfleiderer K; Niesler B; von Deimling A; Opitz C; Breckwoldt MO; Heiland S; Bendszus M; Wick W; Becher B; Platten M
    Nat Commun; 2020 Feb; 11(1):931. PubMed ID: 32071302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
    Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
    Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
    Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X
    Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
    De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
    Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
    Zhai W; Zhou X; Du J; Gao Y
    Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in non-small cell lung cancer harbouring driver mutations.
    Addeo A; Passaro A; Malapelle U; Banna GL; Subbiah V; Friedlaender A
    Cancer Treat Rev; 2021 May; 96():102179. PubMed ID: 33798954
    [No Abstract]   [Full Text] [Related]  

  • 20. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.